BCL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Taken together, these data indicate that targeting BET proteins in CTCL represents a promising novel therapeutic strategy that may be substantially potentiated by combination with BCL2 or HDAC inhibition.